The invention relates to a new combination of hyaluronic acid and macrogol, pharmaceutical compositions containing said combination and the use of the combination and compositions as laxatives.

A first problem is to provide a novel technique for forming hyaluronan into particles. Further, a second problem is to provide a novel technique suitable for production of a composite particle containing an anionic polymer and a peptide. Means for solving the first problem is a composite particle containing an anionic polymer, and a cationic polymer (except for chitosan) having a degree of cationization of 0.2 or more. Means for solving the second problem is to mix an anionic polymer and a peptide in an aqueous solvent having a pH of 5 or less.

A first problem is to provide a novel technique for forming hyaluronan into particles. Further, a second problem is to provide a novel technique suitable for production of a composite particle containing an anionic polymer and a peptide. Means for solving the first problem is a composite particle containing an anionic polymer, and a cationic polymer (except for chitosan) having a degree of cationization of 0.2 or more. Means for solving the second problem is to mix an anionic polymer and a peptide in an aqueous solvent having a pH of 5 or less.

A first problem is to provide a novel technique for forming hyaluronan into particles. Further, a second problem is to provide a novel technique suitable for production of a composite particle containing an anionic polymer and a peptide. Means for solving the first problem is a composite particle containing an anionic polymer, and a cationic polymer (except for chitosan) having a degree of cationization of 0.2 or more. Means for solving the second problem is to mix an anionic polymer and a peptide in an aqueous solvent having a pH of 5 or less.

Disclosed are new recombinant isoforms of human-like lubricin or PRG4 glycoprotein having outstanding lubrication properties and a novel glycosylation pattern, and methods for their manufacture at high levels enabling commercial production.

Disclosed are new recombinant isoforms of human-like lubricin or PRG4 glycoprotein having outstanding lubrication properties and a novel glycosylation pattern, and methods for their manufacture at high levels enabling commercial production.

A composition including, (a) a mineral particle, (b) endothelial cells and mesenchymal cells, and (3) hyaluronic acid, is provided. Moreover, a kit which includes: a syringe, a mineral particle covered with endothelial cells and mesenchymal cells organized in 2 or more cell layers attached to the mineral particle, and hyaluronic acid, is also provided. Last, a method for filling a gap in a bone of a subject in need thereof, including contacting the gap with a composition of: (a) a mineral particle, (b) endothelial cells and mesenchymal cells, and (3) hyaluronic acid is provided.

A composition including, (a) a mineral particle, (b) endothelial cells and mesenchymal cells, and (3) hyaluronic acid, is provided. Moreover, a kit which includes: a syringe, a mineral particle covered with endothelial cells and mesenchymal cells organized in 2 or more cell layers attached to the mineral particle, and hyaluronic acid, is also provided. Last, a method for filling a gap in a bone of a subject in need thereof, including contacting the gap with a composition of: (a) a mineral particle, (b) endothelial cells and mesenchymal cells, and (3) hyaluronic acid is provided.

A composition including, (a) a mineral particle, (b) endothelial cells and mesenchymal cells, and (3) hyaluronic acid, is provided. Moreover, a kit which includes: a syringe, a mineral particle covered with endothelial cells and mesenchymal cells organized in 2 or more cell layers attached to the mineral particle, and hyaluronic acid, is also provided. Last, a method for filling a gap in a bone of a subject in need thereof, including contacting the gap with a composition of: (a) a mineral particle, (b) endothelial cells and mesenchymal cells, and (3) hyaluronic acid is provided.

The present invention provides a method for treating an ocular disease or condition in a subject, comprising administering to the subject’s ocular tissue a composition comprising an effective amount of one or more bioactive agents, wherein the composition is administered with a single-chamber or multi-chamber microchannel delivery device.